GlassScriptPhysician profile
Mergime Imeri
NPI 1215649025
$2,122.93
in general payments reported to CMS, 2019-2025
11 companies · $631 in 2025
The $631 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $533 · 2024: $959 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $670.59 | 2023-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $477.38 | 2023-2025 | Gvoke Hypopen |
| Medtronic, INC. | $186.00 | 2025 | Minimed 780g |
| Sequel Med Tech, LLC | $174.93 | 2025 | Twiist |
| Novo Nordisk INC | $173.60 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Beta Bionics, INC. | $137.87 | 2023 | Ilet Bionic Pancreas |
| Dexcom, INC. | $128.05 | 2024 | Dexcom G7 Gss (161) |
| Tandem Diabetes Care, INC. | $79.52 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $61.85 | 2023-2024 | Jardiance, Mounjaro, Lyumjev |
| Ascendis Pharma Endocrinology INC | $18.44 | 2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $14.70 | 2023 | M-M-R II, Vaxelis, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mergime Imeri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.